TABLE 1.
rv0678 mutations detected in MTBc strains resistant to BDQg
| Genomic coordinate(s)a | Mutation(s) (amino acid and nucleotide change)h | BDQ MIC (μg/ml) | Countryb | Lineage (Coll lineage no.) | Treatment historyc | DR patternd | Frequencye | Eris ΔΔG (kcal/mol)f |
|---|---|---|---|---|---|---|---|---|
| 779005 | G6fs (Del_16–17 gg) | 0.5 | PAK | Delhi-CAS (3) | New | MDR, FQ R | 1 | NA |
| 779016, 779263i | Q9fs (Ins_27 c), Y92fs (Ins_274 a)i | 0.5 | PAK | EAI (1,1,2) | Retreatment | MDR | 1 | NA |
| 779275 | R96W (cgg/Tgg) | 0.25 | BGD | Delhi-CAS (3) | Retreatment | RIF, INH S | 1 | 10 |
| 779321 | M111K (tag/Aag) | 0.25 | BGD | Haarlem (4,1,2,1) | New | RIF, INH S | 1 | 7.84 |
Genomic position in the H37Rv reference strain (GenBank accession number NC_000962.3).
Country of MTBc isolate origin: Pakistan (PAK) or Bangladesh (BGD).
TB patient treatment history: “New,” new TB case; “Retreatment,” patient with previous TB history and treatment.
Drug resistance pattern of the isolates (see Data Set S1 in the supplemental material).
Frequency of mutation in the WHO database.
ΔΔG values calculated with Eris software are reported where applicable (Data Set 2). NA, not applicable.
All the information is reported for each BDQ resistance-related mutation (MIC ≥ 0.25 μg/ml) and for the MTBc isolate tested for BDQ susceptibility.
Where the original codon and the mutated codon are separated by a slash in parentheses, the uppercase letter in the mutated codon represents the changed nucleotide.
There is a one-to-one correspondence between the pair of entries separated by a comma in the “Genomic coordinate(s)” column and the pair in the “Mutation(s)” column.